-
-
-
-
-
-
-
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
-
-
-
-
-
-
-
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
-
-
-
-
-
-
-
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
-
-
-
-
-
-
-
Takeda reports 7-year dengue vaccine data showing sustained protection
-
-
-
-
-
-
-
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
-
-
-
-
-
-
-
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
-
-
-
-
-
-
-
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Po
-
1,177,146 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

